Complexo Hospitalario Universitario A Coruña (CHUAC), A Coruña
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At the Complexo Hospitalario Universitario A Coruña, the Oncology department contributes to research on severe cardiac inflammation, focusing on innovative treatments for acute myocarditis. The studies aim to compare high‑dose pulse corticosteroid therapy with standard supportive care to improve patient outcomes.
- High‑dose pulse corticosteroid therapy for acute myocarditis
- Assessment of cardiac function recovery after novel anti‑inflammatory regimens
- Safety monitoring of intensive steroid protocols in oncology patients
With four active trials and eight investigators, CHUAC leverages a multidisciplinary approach to advance cardiovascular care alongside cancer treatment.
Immune System Diseases
The centre’s research program addresses critical challenges in end‑stage renal disease and related transplant immunology, as well as immune‑targeted therapies for lymphoma. One key goal is to demonstrate that a reduced immunosuppression regimen can maintain graft survival while lowering infection risk.
- Reduced immunosuppression strategies for older adult kidney transplant recipients
- Rituximab and ibrutinib‑based regimens for generalized mantle‑cell lymphoma
- Evaluation of graft and patient survival under modified immunosuppressive protocols
The site’s collaborative environment supports both transplant and hematologic research, reflecting CHUAC’s commitment to improving immune‑related outcomes.
Neoplasms
In the field of neoplasms, CHUAC conducts trials aimed at enhancing therapy tolerance and effectiveness for breast cancer subtypes and lymphomas. Studies explore combination regimens that integrate targeted agents with supportive measures to reduce adverse events while maintaining efficacy.
- Improving sacituzumab govitecan tolerance in metastatic triple‑negative and luminal breast cancer
- Comparative analysis of chemo‑immunotherapy arms for mantle‑cell lymphoma
- Monitoring failure‑free survival across experimental treatment combinations
The oncology team at CHUAC, supported by eight investigators, continues to drive forward innovative cancer research within a European network.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Complexo Hospitalario Universitario A Coruña (CHUAC), A Coruña
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of High-Dose Pulse Intravenous Methylprednisolone Sodium Succinate in Patients with Complicated Fulminant Acute Myocarditis | ASST Grande Ospedale Metropolitano Niguarda | Phase III | Recruiting | Jul 2024 | — |
IMP list
lock Showing 1 of 12 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Basiliximab | 1 | Unknown | 2025-10-10 | 2025-10-10 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.